News

October 18, 2024

Evergreen Theragnostics opens CCK2-VIEW, a Phase II small cell lung cancer clinical trial, in the European Union

Evergreen Theragnostics announces licensing of EVG321 from Medical University of Innsbruck and enters clinical development of Radioligand Therapies in small cell lung cancer

Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into Clinic, Prepare First Commercial Launch, and Expand Industry-Leading CDMO Services

September 25, 2023

UPPI and Evergreen Theragnostics Announce Partnership for Sales and Distribution of OCTEVY™ (Kit for Preparation of Ga 68 DOTATOC Injection), pending FDA approval in 2H 2023

Jubilant Radiopharma and Evergreen Theragnostics Launch Collaboration for the Sale and Distribution of OCTEVY™ (Kit for Preparation of Ga 68 DOTATOC Injection), pending FDA approval in 2H 2023

PharmaLogic and Evergreen Theragnostics Announce Partnership for Sales and Distribution of OCTEVY™ (Kit for Preparation of Ga 68 DOTATOC Injection), pending FDA approval in 2H 2023

CAM-H2 production at Evergreen marks the expansion of Precirix’ clinical trial to the US

RLS and Evergreen Theragnostics launch partnership for sale and distribution of neuroendocrine tumor diagnostic Octevy™ (Kit for Preparation of Ga 68 DOTATOC Injection), pending FDA approval

Orbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticals